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E-mail address: Tyson.Sharp@Nottingham.ac.uk (TLIMD1 is a tumour suppressor gene (TSG) down regulated in 80% of lung cancers with loss also
demonstrated in breast and head and neck squamous cell carcinomas. LIMD1 is also a candidate
TSG in childhood acute lymphoblastic leukaemia. Mechanistically, LIMD1 interacts with pRB,
repressing E2F-driven transcription as well as being a critical component of microRNA-mediated
gene silencing. In this study we show a CpG island within the LIMD1 promoter contains a conserved
binding motif for the transcription factor PU.1. Mutation of the PU.1 consensus reduced promoter
driven transcription by 90%. ChIP and EMSA analysis demonstrated that PU.1 speciﬁcally binds to
the LIMD1 promoter. siRNA depletion of PU.1 signiﬁcantly reduced endogenous LIMD1 expression,
demonstrating that PU.1 is a major transcriptional activator of LIMD1.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Lim domains containing protein 1 (LIMD1) is a bona ﬁde tumour
suppressor gene (TSG) encoded at chromosome 3p21.3, a region
that commonly undergoes homozygous deletion, loss of heterozy-
gosity and epigenetic silencing in many carcinomas, the most stud-
ied being lung [1–3]. Experimentally the ability of the A549 lung
cancer cell line to form lung metastases in a mouse model is signif-
icantly reduced upon stable expression of LIMD1 [4]. Limd1/
mice are predisposed to chemical-induced lung adenocarcinomas
and genetic inactivation of Limd1 in mice heterozygous for onco-
genic K-Ras (G12D) confers markedly increased tumour initiation,
promotion, and mortality [5]. In corroboration with the mouse
model, LIMD1 protein expression is reduced in 80% of lung squa-
mous cell and adeno-carcinomas [5], and in 50% of head and neck
squamous cell carcinomas (HNSCC) [6]. In childhood acute lym-
phoblastic leukaemias 20% of samples have chromosomal deletions
at the 3p21.3 locus with LIMD1 loss ﬂagged as a possible cause of
tumour formation [7]. A reduction in LIMD1 expression is also cor-
related with poor prognosis and survival rates in breast cancer [8].
In the nucleus LIMD1 binds to the Retinoblastoma protein (pRb)
and acts as a co-repressor of E2F-driven transcription [4]. More
recently LIMD1 has been shown to be a critical effector protein
of the miRNA-mediated gene silencing pathway. LIMD1 interactsal Societies. Published by Elsevier
.V. Sharp).simultaneously with eIF4E and core proteins of the microRNA in-
duced silencing complex (miRISC) such as Ago1/2 in what is pro-
posed to be a miRNA-induced inhibitory mRNA closed loop
complex which may precede mRNA deadenylation and subsequent
degradation [9]. It has been shown that several components of the
miRNA pathway, including Ago2, TRBP and Dicer, are deleted or
mutated in cancers [10–13] and LIMD1 loss may also ablate the tu-
mour suppressive effects of this pathway.
Despite the validation of LIMD1 as a bona ﬁde TSG, the processes
controlling LIMD1 gene expression remain to be fully elucidated.
Loss of heterozygosity, gene deletion and promoter methylation
have been shown to cause decreased LIMD1 expression [5,14].
However currently there is no data on the transcriptional control
of LIMD1. Preliminary characterisation of the LIMD1 promoter re-
gion identiﬁed a CpG island within which a 21 bp region was crit-
ical for transcription [5]. However, the identity of the controlling
transcription factor(s) and the possibility of additional positive or
negative regulatory elements within the entire CpG have not been
examined.
PU.1, also referred to as spleen focus forming virus proviral inte-
gration protein (Spi1), was ﬁrst identiﬁed as a putative oncogene in
murine erythroleukaemias [15]. It is a member of the Ets family of
transcription factors, of which there are 28 humanmembers target-
ing over 200 genes including those involved in apoptosis, differen-
tiation, transformation and development [16,17]. Constitutive PU.1
expression is essential for viability of haematopoietic stem cells
(HSCs) [18], with a subsequent reduction in expression causingB.V. Open access under CC BY-NC-ND license.
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creased expression causing differentiation intomacrophages [19]. A
complete loss of PU.1 expression is indicative of committing pre-T
cell to T-cell differentiation [20]. Pathologically PU.1 loss is associ-
ated with acute myeloid leukaemias with as little as a 20% reduc-
tion in expression resulting in an increase in pre-leukaemic
haematopoietic cell number [21]. Reduced PU.1 expression and
PU.1 dependent terminal differentiation markers are found in alve-
olar macrophages of patients suffering from pulmonary alveolar
proteinosis (PAP) [22].
Herein we show that the LIMD1 promoter contains both positive
and negative regulatory elements. Speciﬁcally, we identify a con-
served binding motif for the Ets family transcription factor PU.1
and demonstrate that PU.1 speciﬁcally associates with the LIMD1
promoter at this binding motif. Mutations within the motif disrupt
PU.1 binding and transcriptional activity, and in vivo depletion of
endogenous PU.1 causes loss of LIMD1 protein expression. The
implications of our ﬁndings with respect to LIMD1 regulation in
haematopoietic derived malignancies are discussed.2. Materials and methods
2.1. Promoter mapping analysis
As a point of reference the unconﬁrmed transcriptional start
site (TSS) for LIMD1 was assigned according to the NCBI reference
sequence NM_014240.2 (nucleotide 45636323 on the primary
chromosome 3 ref assembly NC_000003.11), which is 49 bp up-
stream from the AUG (45636372). The LIMD1 promoter along with
a series of ten 18–35 bp internal deletions (ID1–10) corresponding
to internal regions 1–10 (IR1–10) (Supplementary data Fig. 1) were
previously cloned as described [5] into a pGL4.10 [luc2] (Promega)
ﬁreﬂy luciferase reporter vector. U2OS cells were co-transfected
with 50 ng of promoter reporter and 5 ng of a Renilla luciferase
vector (for normalisation). Luciferase activity was assayed using
the Dual-Luciferase Reporter Assay System (E1960, Promega)
24 h post-transfection.
2.2. Bioinformatic analysis
The LIMD1 promoter, encompassing 1990 bp upstream of the
TSS, was scrutinised for putative transcription factor binding sites
using MatInspector (http://www.genomatix.de/products/MatIn-
spector/) with the Matrix Family Library Version 8.1 (Supplemen-
tary Table 1). The default thresholds were utilised, with a perfect
and good matrix match scoring 1.00 and >0.80, respectively. For
promoter homology/identity comparisons, genomicDNA sequences
from mammalians that express PU.1 as identiﬁed using Homolo-
Gene (http://www.ncbi.nlm.nih.gov/homologene/) were obtained
using the Ensembl Genome Browser (www.ensembl.org) and
aligned using ClustalW (www.ebi.ac.uk/clustalw) and BioEdit
Sequence Alignment Editor.
2.3. Point mutagenesis of IR5
The core putative PU.1 consensus binding sequence 50-TTCC of
the sense strand (50-GGAA of the anti-sense strand) within IR5,
which maps to 673 relative to the TSS was mutated from 50-TTCC
to 50-TTTT using site directed mutagenesis (QuikChange XL Site-
Directed Mutagenesis Kit, Stratagene #200517). Primers used were
50 GCCTGGCGCACTCCTTTTGCGTCCCGCCGCCCTCCGG (forward)
and 50 CCGGAGGGCGGCGGGACGCAAAAGTGAGTGCGCCAGGC (re-
verse). As a control another C to T point mutation was introduced
further downstream at 660 to the TSS, but still within the same
internal region using 50 GCCTGGCGCACTCACTTCCGCGTCCCGCT-GCCCTCCGG (forward) and 50 CCGGAGGGCAGCGGGACGCGGAAGT-
GAGTGCGCCAGGC (reverse). Both mutated plasmids were then re-
verse mutated back to the wild type plasmid as controls to ensure
no other background mutations had been introduced through PCR.
2.4. siRNA targeted depletion and qRT-PCR analysis
siRNA targeted against PU.1, LIMD1, Ets-1 or a scrambled control
sequence was electroporated into the human leukaemic monocytic
lymphoma U937 cell line using the Amaxa Cell Line Nucleofector
Kit V (Lonza VCA-1003) on a Nucleofector II electroporator (Lonza)
utilising the U937 cell speciﬁc programme. siRNA targeted against
LIMD1, PU.1, Elk-1 or a control scrambled sequence were transfec-
ted into U2OS using INTERFERin™ (Polyplus-transfection SA,
Illkirch, France) as per manufacturer’s protocol. Gene knockdown
was assayed 48 h post-transfection. RNA and protein were simulta-
neously extracted from U937 cells using an RNA/Protein Puriﬁca-
tion kit (Norgen Biotek Corp. 23000). RNA was extracted from
U2OS using RNAqueous Micro Kit (Ambion AM1931). Protein
knockdown was assayed by Western blot with rabbit monoclonal
anti-PU.1 (Cell Signalling #2266) (for U937 cell knockdown only
as the antibody could not detect the very low levels of endogenous
PU.1 in U2OS cells), mouse monoclonal anti-LIMD1 [4], mouse
monoclonal anti-Ets-1 (Transduction Laboratories E34620), rabbit
polyclonal anti-Elk-1 (Santa Cruz SC-22804) and anti-b-actin
(Sigma–Aldrich A3853) as a loading control. mRNA knockdown
was quantiﬁed by qRT-PCR. cDNA was synthesised (Transcriptor
High Fidelity cDNA Synthesis Kit, Roche Applied Science) and
qRT-PCR performed using the primers PU.1 50 CAGGGGATCTG
ACCGACTC (forward) and 50 GCACCAGGTCTTCTGATGG (reverse)
and the b-Tubulin housekeeper 50 ATACCTTGAGGCGAGCAAAA (for-
ward) and 50 CTGATCACCTCCCAGAACTTG (reverse).
2.5. PU.1 subcloning
Human PU.1 cDNA was kindly provided by A. Rizzino (Univer-
sity of Nebraska Medical Centre). The cDNA was subcloned with
the addition of 6N-terminal amino acids into a pcDNA4/HisMax
TOPO vector (Invitrogen K86420) (further referred to as pcDNA4)
using the primers 50 CGCGAATTCCAGATGTTACAGGCGTGCAAAAT-
GGAAGGGTTTCCCCTCGTCCCCCCTCCATC (forward) and 50 GCGGG-
ATCCTCAGTGGGGCGGGTGGCGCCGCTCGGCCAGGCCCCCGCGGCCC-
AGCACTTCGC (reverse). HA tagged PU.1 was generated by cut and
pasting PU.1 cDNA from pcDNA4-PU.1 into a pCMV5-HA vector
utilising the incorporated EcoR1 and BamH1 restriction sites.
2.6. Chromatin immunoprecipitation
Endogenous expression of PU.1 and LIMD1 in U937 cells was
conﬁrmed by Western blot using anti-PU.1 (Cell Signalling
#2266) and anti-LIMD1 [4]. 8  106 U937 cells were serum starved
overnight prior to 30 min stimulation with 20% FCS supplemented
RPMI. Cells were ﬁxed (1% paraformaldehyde, 10 min, 37 C) and
quenched with 2  10 ml 0.125 M glycine/PBS washes. Cells were
resuspended in 1 ml harvesting buffer (0.125 M glycine, 1 mM
EDTA, 1 mM PMSF in PBS), pelleted (3000 rpm, 4 C, 10 min) and
lysed in 100 ll lysis buffer (50 mM Tris–HCl, pH 8.0, 1% SDS,
10 mM EDTA). DNA was sheared to 200–600 bp by sonication then
centrifuged (13 000 rpm, 4 C, 10 min). Lysates were diluted 10-
fold with dilution buffer (20 mM Tris–HCl, pH 8.0, 1% Triton-X-
100, 2 mM EDTA, 150 mM NaCl) and pre-cleared for 1 h with
IgG/Protein G before addition to 40 ll ExactaCruz™ E IP Matrix
(Santa Cruz 45042) with either 10 ll anti-PU.1 (Cell Signalling
#2266) or equalised isotype control antibody conjugated. After
an overnight incubation IP beads were washed 4 for 10 min with
wash buffer (10% lysis buffer/dilution buffer), 2 10 min TE and
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links were reversed (0.2 M NaCl, 65 C, 6 h), proteinase K treated
and DNA puriﬁed (QIAquick PCR Puriﬁcation Kit, Qiagen 28104).
PCR was performed using the CD11b promoter as a positive control
for PU.1 binding as previously described [23] and LIMD1 speciﬁc
primers 50 GCAGCAGGGACTGCGCCTGGCG (forward) and 50
GGGGCTGGCGGCCCATTGTCCG (reverse), to amplify 751 to 650
of the promoter. To show speciﬁcity for the ID5 region a set of
primers upstream (1779 to 1630) of ID5 were included.
2.7. Production of recombinant Elk-1 and PU.1 Ets domain and nuclear
extracts
The DNA-binding Ets domains of Elk-1 and PU.1 were subcloned
into the pQE60 background, generating proteins that contained
both His and HA epitope tags. These plasmids were expressed in
the SG13009 strain of Escherichia coli and the resulting recombi-
nant protein puriﬁed on nickel agarose beads (Qiagen). A total of
25 ng of recombinant Ets protein was used in subsequent electro-
phoretic mobility shift assays (EMSA). Nuclear extracts were pre-
pared from HEK 293T cells either untransfected or transfected
with HA-PU.1 or HA-Elk-1 using hypotonic and hypertonic lysis
and ﬂash frozen in liquid N2 as previously described [24].
2.8. EMSAs
Oligonucleotides representing the wild type IR5 sequence (WT:
50 32P-CTCACTTCCGCGTCCCGCCGC (forward) and 50 GCGGCGGGAC
GCGGAAGTGAG (reverse) or point mutated (MT) IR5 sequence
(MT1: 50 CTCACTTTTGCGTCCCGCCGC (forward) and 50 GCGGCGGG
ACGCAAAAGTGAG (reverse); MT2: 50 CTCACGGCCGCGTCCCGCCGC
(forward) and 50 GCGGCGGGACGCGGCCGTGAG (reverse) were
annealed. A mix of 4 binding buffer (140 mM KCl, 18 mM MgCl2,
12 mM spermidine), Poly dI/dC (26 lg/ml ﬁnal concentration),0
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Fig. 1. Identiﬁcation of a transcriptionally crucial 21 bp region of the LIMD1 promoter by
ﬁreﬂy luciferase vector with the 10 internal deletions (ID) and previously identiﬁed C
deletions as indicated, lysed 24 h post-transfection and ﬁreﬂy luciferase activity assayedsheared Herring sperm (100 lg/ml ﬁnal concentration) and nuclear
extract/recombinant protein was made up. The volume was made
up with incubation buffer (10 mM HEPES, pH 7.8, 5% glycerol,
50 mM KCl, 1 mM EDTA, 1 mM DTT). Antibody or cold probe
(either wt or containing point mutations) was added and the reac-
tion incubated at room temperature for 1 h. Labelled probe was
added and reactions incubated for a further 10 min at room tem-
perature before loading onto a 5% polyacrylamide gel (0.5  TBE).
Gels were dried and developed using a Fuji-ﬁlm LAS-3000 phos-
phor-imager.
3. Results
3.1. The CpG Island within the LIMD1 promoter contains both positive
and negative regulatory elements
A series of 10 consecutive deletions within the CpG Island of
the LIMD1 gene were created in order to identify positive or neg-
ative regulatory elements (Fig. 1A). The ID5 mutant (678 to
658 relative to the transcriptional start site) reduced levels of
promoter transcription by 90% (Fig. 1B), signiﬁcantly greater than
the ID1, 8 and 9 mutants which all exhibited a 65% reduction,
implicating these regions of the promoter as containing positive
regulatory elements (Fig. 1B). Conversely, ID4 and ID6 gave 50%
and 100% increases in transcription, respectively, implicating
these regions as negative regulatory elements (Fig. 1B). ID2, 3
and 7 showed approximately 25% increases in transcription and
ID10 had no signiﬁcant change in transcriptional activity
(Fig. 1B). Comparable results were also obtained in the A549 lung
cancer cell line with the ID5mutant (Supplementary data Fig. 2),
however the decrease in transcriptional activity was not as great
when compared to U2OS cells (60% compared to 90%) implying
that tissue-speciﬁc factors may associate with this promoter
region.ATG
+50-390-523
IΔ7 IΔ8 IΔ9 IΔ10 luciferase
mutational analysis. (A) Schematic diagram of the LIMD1 promoter cloned into pGL4
pG Island indicated. (B) U2OS cells were transfected with the internal promoter
with values normalised to renilla luciferase.
1092 D.E. Foxler et al. / FEBS Letters 585 (2011) 1089–10963.2. An Ets family consensus sequence is conserved between mammals
within the LIMD1 promoter
To determine why the internal region 5 (IR5) was critical for
transcription, LIMD1 promoter sequences from different mammali-
ans were scrutinised and found to be perfectly conserved across 13
species (Fig. 2A). The 30 downstream IR7 was also conservedFig. 2. IR5 contains a conserved PU.1 consensus that is required for transcription from th
species was extracted from the Ensembl genome browser and aligned using ClustalW
scrutinisation of IR5 using MatInspector identiﬁed a putative PU.1 binding consensus seq
the WT consensus are shown (CC-TT and C-T). In addition we performed reverse mutage
outside of this consensus (T-C). All mutated promoter reporters together with WT and
consensus; italics and underlined – mutated bases.(Fig. 2A), however as its deletion did not cause a signiﬁcant loss
in transcription, no further investigations were performed on this
region. To identify possible transcription factor binding sites with-
in the critical IR5 of the LIMD1 promoter, the sequence was scruti-
nised using MatInspector. This analysis identiﬁed a consensus
sequence for the Ets domain containing family member PU.1, with
a Matrix score of 0.989 (1.0 is a perfect match and 0.8 is a goode LIMD1 promoter. (A) LIMD1 promoter sequences from different LIMD1 expressing
. Perfect homology is observed at the IR5 and within the IR7 consensus. Further
uence. (B) Point mutagenesis of the PU.1 binding consensus sequence compared to
nesis to restore the PU.1 consensus (TT-CC) and reverse single conserved mutation
ID5 LIMD1 promoters were analysed in reporter assays as in Fig. 1B. Bold – PU.1
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Fig. 3. ChIP analysis of PU.1 binding to the LIMD1 promoter. (A) Western blot
analysis of U937 cell extracts for endogenous LIMD1 and PU.1 proteins as indicated.
(B) Endogenous ChIP was performed with anti-PU.1 speciﬁc antibody (a-PU.1) or
isotype IgG (control) using U937 nuclear extracts. Immunoprecipitated DNA was
analysed via PCR utilising primers for the CD11b promoter (as a positive control),
the LIMD1 promoter encompassing IR5, or primers targeted to a region within the
LIMD1 promoter but upstream of IR5 (US LIMD1) as a negative control for binding.
Water only was used for PCR control for each primer set (PCR control).
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the anti-sense strand 50-GCGGAAGTG (Fig. 2A). No other potential
transcription factor binding sites were identiﬁed within the core
IR5 region.
3.3. Mutation within the Ets binding domain consensus reduces
transcription by 90%
To assess the requirement of the putative Ets family transcrip-
tion factor consensus within IR5 for transcriptional control, the
wild type LIMD1 promoter-luciferase construct was mutated with-
in the binding consensus from CC to TT (Fig. 2B). This 2 base muta-
tion resulted in a 90% decrease in promoter expression, similar to
levels obtained with the 21 bp ID5 deletion (Fig. 2B). Reverse
mutagenesis back to wild type sequence restored transcriptional
activity to levels approaching that of wild type (Fig. 2B). As a con-
trol for consensus speciﬁcity, mutation of another cytosine within
the IR5, but not part of the consensus motif, did not affect tran-
scription. One way ANOVA statistical analysis conﬁrmed values
were not signiﬁcantly different to that of WT (MS = 2.777779,
F = 2.753897 and P-value = 0.088575).
3.4. ChIP analysis of IR5 within the LIMD1 promoter
PU.1 is a well established transcription factor within the hae-
matopoietic lineage, and so in order to establish the physiological
role that PU.1 may have as a regulator of LIMD1 expression, we per-
formed endogenous ChIP analyses using the U937 histiocytic lym-
phoma cell line. Endogenous expression of LIMD1 and PU.1 in this
cell line was ﬁrstly conﬁrmed by Western blot (Fig. 3A). In subse-
quent chromatin immunoprecipitation experiments, PU.1 co-
immunoprecipitated the DNA region speciﬁcally spanning 751
to 650 of the LIMD1 promoter that includes IR5 (Fig. 3B). Primers
were also included to amplify DNA further upstream of IR5 (but
still within the promoter) however no amplicon was detected indi-
cating the ChIP assay was speciﬁc for the PU.1 consensus contain-
ing region (Fig. 3B). As a positive control the primer set for the
CD11b promoter (previously established to bind PU.1) was also in-
cluded (Fig. 3B) [23,25]. Identical results with the LIMD1 and CD11b
DNA elements were obtained using exogenously transfected
pcDNA4 PU.1 in HEK 293T cells (Supplementary data Fig. 3).
3.5. PU.1 and the PU.1 Ets domain alone bind to the IR5 DNA consensus
in vitro
To support our ﬁndings from ChIP analyses we next performed
electrophoretic mobility shift assays with nuclear extracts contain-
ing exogenous HA-tagged PU.1 and a 32P-labelled IR5 DNA consen-
sus probe (Fig. 4A). A supershift was seen with both the aPU.1 and
aHA antibodies but not with three control antibodies (aEts-1, Elk-
1 and STAT3) (Fig. 4A). We then examined if the Ets domain of PU.1
alone could bind speciﬁcally to the IR5 sequence. Using recombi-
nant HA-tagged PU.1 Ets domain in an EMSA assay we observed
a supershift with an aHA antibody (Fig. 4B). The recombinant
HA-tagged Ets domain of Elk-1 did not bind to this sequence
(Fig. 4B, lane 4). Furthermore, in an EMSA assay with cold compet-
itor DNA consensus probe, only the wild type consensus was able
to compete, whereas two different PU.1 consensus point mutants
(Mt1/Mt2) were unable to compete out labelled wild-type probe
(Fig. 4B, lanes 5–7).
3.6. PU.1 siRNA targeted depletion results in loss of LIMD1 expression
We next reasoned that if PU.1 was a major positive transcrip-
tional activator of LIMD1 then depletion of PU.1 should result in
down-regulation of LIMD1 mRNA and therefore protein levels.For continuity with the endogenous ChIP assay performed
(Fig. 3B), we depleted endogenous PU.1 in U937 cells. siRNA deple-
tion of endogenous PU.1 (Fig. 5A) signiﬁcantly reduced LIMD1 pro-
tein levels. siRNA targeted depletion of (the Ets family member)
Ets-1 was also performed. Depletion of Ets-1 did not alter LIMD1or
PU.1 protein or PU.1 mRNA levels (Fig. 5A and B). As a control for
speciﬁcity of siRNA depletion of PU.1, siRNA targeted against
PU.1 did not affect Ets-1 protein levels (Fig. 5A), demonstrating
that reduced LIMD1 expression was speciﬁc for PU.1 depletion.
We also performed PU.1 knockdown in U2OS where levels were
only detectable by qRT-PCR (Fig. 5D). As with U937 cells siRNA tar-
geted depletion of PU.1 resulted in signiﬁcantly reduced LIMD1
protein levels, as detected by Western blot (Fig. 5C). siRNA deple-
tion of Elk-1 did not affect LIMD1 protein levels or cause a signiﬁ-
cant change in PU.1 mRNA levels. Of note is a decrease in the Elk-1
protein level upon knockdown of LIMD1, possibly implicating
LIMD1 as a regulatory protein of Elk-1. This effect is also partially
seen with PU.1 directed siRNA however this can most probably be
attributed to the reduced LIMD1 protein levels as a result of PU.1
knockdown.
4. Discussion
The use of internal deletion mutants within the CpG Island has
allowed us to identify core regions of promoter activity. Through
reporter assays we observed areas of the promoter likely to contain
positive and negative regulatory elements; however most notable
was the IR5. Within this region we identiﬁed a conserved motif
for the Ets transcription factor PU.1, and conﬁrmed the functional-
ity and physiological importance of PU.1 binding to this element
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Fig. 4. EMSA supershift analysis of the IR5 with PU.1 and competition with mutant oligos. (A) Nuclear extracts from untransfected HEK 293T cells (lane 2) or cells transfected
with a vector for HA-PU.1 (lanes 3–8) were incubated with radiolabelled IR5 DNA alone or in the presence of antibodies against PU.1, Ets-1, Elk-1, the HA epitope and STAT3,
as indicated. PU.1 complexes are indicated with an arrow. The partial supershift with the HA antibody likely reﬂects a degree of translation initiation at an internal AUG. (B) A
recombinant HA-tagged Ets domain of PU.1 was incubated with IR5 DNA alone (lane 2), in the presence of anti-HA antibody (lane 3) or 100-fold excess of unlabelled wt or
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PU.1 is a major transcriptional activator of LIMD1.
PU.1 was initially identiﬁed as binding to the core sequence 50-
GAGGAA [26], however variations within the preceding and fol-
lowing bases around the GGAA motif have since been identiﬁed.
Recent ChIP-Seq analysis of PU.1 binding in macrophages and
B-cells revealed the core binding motif for PU.1 (GGAA) is com-
monly preceded by G/A/C then A/C/G, and followed by, in the
majority of sequenced motifs, by GTG [27]. This correlates well
with the IR5 identiﬁed sequence of GCGGAAGTG. Furthermore,
other characterised macrophage and B lineage associated genes
under PU.1 also have sequence homology to the IR5 sequence.
Secretory interleukin-1 receptor antagonist (IL-1Ra) has the con-
sensus GCGGAAATA [28], whilst Toll-like receptor 4 (TLR4) has
the consensus GAGGAAGTG [29].
PU.1 has been extensively studied within the haematopoietic
cell lineage with down regulation of this transcription factor lead-
ing to leukaemic transformation [21,30]. LIMD1 has not been stud-
ied in HSC lineage physiology or pathology, with the exception of
one publication that ﬂagged chromosomal loss that encompasses
the LIMD1 gene as being possibly causative of childhood acute lym-
phoblastic leukaemia [7]. We have shown PU.1 binds to the LIMD1
promoter in the LIMD1 expressing U937 lymphoma cell line
(Fig. 3B) and that PU.1 loss is causative of LIMD1 loss (Fig. 5). These
experimental ﬁndings, in corroboration with the published tumoursuppressive properties of LIMD1, could provide new insights into
other HSC lineage derived malignancies. This may be applicable
in leukaemias where PU.1 loss is already a well characterised phe-
nomenon [21,30].
Published evidence suggests LIMD1 is silenced through genetic
alterations that reduce expression levels rather than mutations to
coding regions that affect activity [5]. Although a recent study
has identiﬁed a small minority of head and neck squamous carci-
noma patients with point mutations and one frame shift mutation
[31], there is currently no reported evidence indicating such point
mutations affect LIMD1 function. If the tumour suppressive effects
of LIMD1 are applicable to HSC lineage related malignancies then
identiﬁcation of PU.1 as a major transcriptional activator of LIMD1
could lead to the development of innovative therapies to prevent
or reactivate LIMD1 expression. Furthermore, as well as screening
for LIMD1 gene loss as a pathological indicator bisulphite sequenc-
ing of the critical PU.1 consensus would also be indicative of LIMD1
expression (Fig. 2B).
PU.1 is an essential transcription factor in osteoclastogenesis,
with PU.1 expression up-regulating miR-223 expression, which in
turn down regulates NFI-A levels causing osteoclast differentiation
[32,33]. A functional miRNA mediated gene silencing pathway is
required for osteoclastogenesis: loss of the miRNA-silencing
associated proteins DGCR8, Dicer1 and Ago2 impairs osteoclast
differentiation and function [33]. LIMD1 binds Ago2 and is an
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D.E. Foxler et al. / FEBS Letters 585 (2011) 1089–1096 1095important component of miRNA mediated silencing [9], so it is
possible that reduced expression of LIMD1 may also impair osteo-
clast differentiation. During RANK-L mediated osteoclast differen-
tiation, through TRAF6, PU.1 is upregulated [33,34]. Concurrent
to this, Limd1 protein levels are also upregulated, where it inter-
acts with TRAF6 to inﬂuence osteoclast differentiation [35]. In light
of our ﬁndings it is feasible to link these two independent studies.
Up-regulation of PU.1 induces expression of LIMD1, which may
subsequently interact with TRAF6 to induce osteoclast differentia-
tion. Furthermore, as increased LIMD1 expression increases the po-
tency of miRNA silencing [9], down-regulation of NFI-A through
mir-223 mediated miRNA silencing may be increased, further
increasing osteoclastogenesis. Therefore in osteoclastogenesis we
propose PU.1 may have a two pronged positive effect; ﬁrstly, as a
transcriptional regulator of osteoclastogenesis speciﬁc miRNAs
[36] and secondly, by increasing LIMD1 protein levels and its asso-
ciated miRNA and TRAF6 interactions.
There is little published literature on the pathogenic role of
deregulated PU.1 in non-HSC derived biology. Of note is an obser-
vation in the lung airway epithelia in allergic asthma where inhibi-
tion of microRNA-126 indirectly causes increased expression of
PU.1, which consequently suppresses GATA3 expression and thus
the GATA3 induced inﬂammatory response [37,38]. Our data also
demonstrate a consistent reduction in transcriptional activity of
LIMD1 with the ID5 mutant in the A549 lung cancer cell line whichis thought to derive from alveolar basal epithelial cells (Supple-
mentary data Fig. 2).
LIMD1 has reduced expression within 75–83% of lung carcino-
mas [4,5], with gene deletion, loss of heterozygosity and epigenetic
silencing accounting for 70% of reductions in LIMD1 expression. If
PU.1 is expressed in lung tissue, then the 5–10% shortfall in tu-
mours with unexplained mechanisms for LIMD1 loss may be
attributed to PU.1 gene silencing and/or regulation. Clearly, the siR-
NA mediated depletion of PU.1 and the consequent loss of LIMD1
expression (Fig. 5) supports this possibility.
As well as being a transcriptional activator, PU.1 has also been
shown to associate with DNA methyl transferases 3a and b
(Dnmt3a/b) and induce silencing of target genes with PU.1 binding
sites through methylation, speciﬁcally exempliﬁed by the p16INK4A
tumour suppressor gene [39]. LIMD1 itself is epigenetically si-
lenced through promoter methylation in the MDA-MB435 breast
cancer cell line, with promoter methylation also evident in 26%
of human lung tumours when compared to normal matched lung
tissue [5,14]. In light of the dual function of PU.1, the role of PU.1
during LIMD1-loss associated transformation remains to be eluci-
dated. In silico screening of the promoter identiﬁed a second puta-
tive Ets domain/PU.1 binding site at 120 relative to the TSS. As
point mutations of the PU.1 motif within IR5 (Fig. 2B) resulted in
a 90% decrease in transcription, it is likely that the second PU.1
site is not involved in transcriptional activation. However during
1096 D.E. Foxler et al. / FEBS Letters 585 (2011) 1089–1096transformation it could act as a site for PU.1 (coupled with
Dnmt3a/b) binding, causing epigenetic silencing of LIMD1.
In conclusion we have shown that PU.1 is a major regulator of
LIMD1 expression and thus it will be of interest to re-examine
PU.1 related malignancies in light of these ﬁndings for deregulation
of LIMD1 tumour suppressive functions such as miRNA-mediated
silencing and pRB co-repression [4,9].
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